Ascentage Pharma Group International Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Ascentage Pharma Group International yıllık ortalama 10.4% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 31.7% annual. Gelirler yılda ortalama 73.2% oranında büyüyor .

Anahtar bilgiler

10.4%

Kazanç büyüme oranı

29.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi	11.0%
Gelir büyüme oranı	73.2%
Özkaynak getirisi	-46.4%
Net Marj	-39.9%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

What Ascentage Pharma Group International's (HKG:6855) P/S Is Not Telling You

Dec 23

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Sep 04

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

Aug 26

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Jun 18

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

May 03

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Mar 30

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Feb 17

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Dec 20

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Oct 28

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

Aug 27

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Aug 23

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Jun 19

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Dec 04

Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?

Aug 30

Gelir ve Gider Dağılımı

Ascentage Pharma Group International nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SEHK:6855 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	903	-360	378	841
31 Mar 24	563	-643	377	774
31 Dec 23	222	-926	376	707
30 Sep 23	239	-902	363	709
30 Jun 23	257	-879	349	712
31 Mar 23	233	-881	339	727
31 Dec 22	210	-883	328	743
30 Sep 22	160	-848	299	767
30 Jun 22	111	-812	270	790
31 Mar 22	69	-797	231	778
31 Dec 21	28	-782	191	766
30 Sep 21	25	-759	167	699
30 Jun 21	23	-735	143	631
31 Mar 21	18	-706	137	598
31 Dec 20	12	-678	130	565
30 Sep 20	14	-922	146	540
30 Jun 20	15	-1,167	162	516
31 Mar 20	15	-1,324	162	490
31 Dec 19	15	-1,481	162	464
30 Sep 19	11	-1,171	133	418
30 Jun 19	7	-862	104	372
31 Mar 19	7	-604	97	311
31 Dec 18	7	-345	90	250
31 Dec 17	6	-119	26	119
31 Dec 16	8	-108	22	103

Kaliteli Kazançlar: 6855 şu anda kârlı değil.

Büyüyen Kar Marjı: 6855 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 6855 kârlı değildir, ancak son 5 yılda zararlarını yılda 10.4% oranında azaltmıştır.

Büyüme Hızlandırma: 6855 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 6855 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 7.4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 6855 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -46.43% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/10 11:18
Gün Sonu Hisse Fiyatı	2025/01/10 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Ascentage Pharma Group International 13 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yang Huang	BofA Global Research
Jin Zhang	China International Capital Corporation Limited
Wangbin Zhou	China International Capital Corporation Limited

Ascentage Pharma Group International Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

Recent updates

Ascentage Pharma Group International Announces Board and Committee Changes, Effective January 2, 2025

Ascentage Pharma Group International has filed a Follow-on Equity Offering in the amount of $100 million.

What Ascentage Pharma Group International's (HKG:6855) P/S Is Not Telling You

Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax

Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors

Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up

Consensus revenue estimates increase by 40%

Forecast to breakeven in 2026

Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

New major risk - Revenue and earnings growth

Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration

Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Shareholder dilution

Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up

Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351)

New minor risk - Share price stability

Ascentage Pharma Group International Announces Board and Committee Changes

Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting

Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year

Consensus EPS estimates fall by 15%

Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?

Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia

Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib

Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR

Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients

Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports

Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt

Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc

Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia

Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE

Consensus revenue estimates fall by 12%

Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price

Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial

Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023

Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax

Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All)

Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt

Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST

Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates decrease by 22%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million.

Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax

Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib

Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?

Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License

Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B

Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb

Co-Founder recently bought HK$159k worth of stock

Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting

Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting